May 9, 2018Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden Read more »
July 1, 2018Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors Read more »
May 29, 2018PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab Read more »
February 1, 2019Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients Read more »
November 1, 2017Comprehensive characterization of solid tumor immune profiles for precision immunotherapy using Immune Report Card℠ Read more »
November 1, 2017Overexpression of immunotherapeutic targets in the immune desert phenotype Read more »
June 1, 2017Tumor Mutational Burden (TMB): Assessment of inter-and intra-tumor heterogeneity Read more »
June 1, 2020Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies Read more »
